Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit
- PMID: 22893223
- DOI: 10.1007/s00134-012-2675-0
Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit
Abstract
Purpose: The changed epidemiology of extended spectrum beta-lactamases (ESBL), the spread to the community and the need for prudent use of carbapenems require updated knowledge of risk factors for colonization with ESBL-producing enterobacteriaceae (ESBL-PE).
Methods: An 8-month prospective study in the medical ICU of an 850-bed general and university-affiliated hospital.
Results: Of 610 patients admitted, 531 (87 %) had a rectal swab obtained at admission, showing a 15 % (82 patients) ESBL-PE carriage rate, mostly of E. coli (n = 51, 62 %); ESBL-PE caused 9 (3 %) infections on admission. By multivariable analysis, transfer from another ICU (OR = 2.56 [1, 22]), hospital admission in another country [OR = 5.28 (1.56-17.8)], surgery within the past year [OR = 2.28 (1.34-3.86)], prior neurologic disease [OR = 2.09 (1.1-4.0)], and prior administration of third generation cephalosporin (within 3-12 months before ICU admission) [OR = 3.05 (1.21-7.68)] were independent predictive factors of colonization by ESBL-PE upon ICU admission. Twenty-eight patients (13 % of those staying for more than 5 days) acquired ESBL carriage in ICU, mostly with E. cloacae (n = 13, 46 %) and K. pneumoniae (n = 10, 36 %). In carriers, ESBL-PE caused 10 and 27 % of first and second episodes of ICU-acquired infections, respectively.
Conclusion: We found a high prevalence of ESBLE-PE colonization on admission to our ICU, even in the subgroup admitted from the community, but few first infections. Identifying risk factors for ESBL-PE colonization may help identifying which patients may warrant empiric ESBL-targeted antimicrobial drug therapy as a means to limit carbapenem use.
Comment in
-
For control of colonisation with extended-spectrum β-lactamase-producing bacteria, SDD does work.Intensive Care Med. 2013 Mar;39(3):539. doi: 10.1007/s00134-012-2780-0. Epub 2013 Jan 4. Intensive Care Med. 2013. PMID: 23287872 No abstract available.
-
Control of colonisation with extended-spectrum β-lactamase-producing bacteria: reply to Zandstra et al.Intensive Care Med. 2013 Mar;39(3):540. doi: 10.1007/s00134-012-2781-z. Epub 2013 Jan 4. Intensive Care Med. 2013. PMID: 23287873 No abstract available.
Similar articles
-
ESBL-colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcome.Infect Control Hosp Epidemiol. 2019 Apr;40(4):408-413. doi: 10.1017/ice.2019.5. Epub 2019 Feb 21. Infect Control Hosp Epidemiol. 2019. PMID: 30786948
-
Cessation of screening for intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in a low-endemicity intensive care unit with universal contact precautions.Clin Microbiol Infect. 2018 Apr;24(4):429.e7-429.e12. doi: 10.1016/j.cmi.2017.08.005. Epub 2017 Sep 26. Clin Microbiol Infect. 2018. PMID: 28962997
-
Prior Carriage Predicts Intensive Care Unit Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Am J Trop Med Hyg. 2022 Jan 10;106(2):525-531. doi: 10.4269/ajtmh.20-1436. Am J Trop Med Hyg. 2022. PMID: 35008044 Free PMC article.
-
Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: a systematic review.Crit Care. 2019 May 14;23(1):170. doi: 10.1186/s13054-019-2460-3. Crit Care. 2019. PMID: 31088542 Free PMC article.
-
How Should We Treat Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae?Semin Respir Crit Care Med. 2017 Jun;38(3):287-300. doi: 10.1055/s-0037-1603112. Epub 2017 Jun 4. Semin Respir Crit Care Med. 2017. PMID: 28578553 Review.
Cited by
-
Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018.Antimicrob Resist Infect Control. 2021 Mar 7;10(1):50. doi: 10.1186/s13756-021-00918-7. Antimicrob Resist Infect Control. 2021. PMID: 33678189 Free PMC article.
-
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Intensive Care Med. 2015 May;41(5):776-95. doi: 10.1007/s00134-015-3719-z. Epub 2015 Mar 20. Intensive Care Med. 2015. PMID: 25792203 Free PMC article. Review.
-
Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design.Eur J Clin Microbiol Infect Dis. 2013 May;32(5):581-95. doi: 10.1007/s10096-012-1795-3. Epub 2012 Dec 27. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23268203 Review.
-
Burden and Management of Multidrug-Resistant Organisms in Palliative Care.Palliat Care. 2017 Dec 19;10:1178224217749233. doi: 10.1177/1178224217749233. eCollection 2017. Palliat Care. 2017. PMID: 29317826 Free PMC article. Review.
-
Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices.Curr Infect Dis Rep. 2013 Oct 12. doi: 10.1007/s11908-013-0373-x. Online ahead of print. Curr Infect Dis Rep. 2013. PMID: 24122401
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous